Manufacturers: 858 Therapeutics
Oral, potent, and selective PARG inhibitor. PARG inhibition targets DNA repair deficiencies in BRCA-mutated tumors, aiming for synthetic lethality and tumor cell death.
2 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
